We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis.
- Authors
Ryser, Fabio S.; Yalamanoglu, Ayla; Valaperti, Alan; Brühlmann, Catrin; Mauthe, Tina; Traidl, Stephan; Soyka, Michael B.; Steiner, Urs C.
- Abstract
Background: Dupilumab, a monoclonal anti‐IL‐4Rα antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS). Clinical studies had reported a transient increase in blood eosinophils during dupilumab therapy. This study aimed to assess the impact of elevated blood eosinophils on clinical outcome and to investigate the cause of high blood eosinophil levels under dupilumab therapy. Methods: Patients suffering from diffuse type 2 CRS treated with dupilumab were examined on days 0, 28, 90, and 180 after therapy start. Sino‐Nasal‐Outcome‐Test Score (SNOT‐22), Total Nasal Polyp Score (TNPS), and blood samples were collected. Cytokine measurements and proteomics analysis were conducted. Flow cytometry analysis measured receptor expression on eosinophils. Results: Sixty‐eighty patients were included. Baseline eosinophilia ≥0.3G/L was observed in 63.2% of patients, and in 30.9% of patients, eosinophils increased by ≥0.5G/L under dupilumab. Subjects with eosinophilia ≥0.3G/L at baseline had the best SNOT‐22 mean change compared to no eosinophilia. Eosinophil elevation during dupilumab therapy had no impact on clinical scores. The eosinophil adhesion molecule VCAM‐1 decreased significantly during therapy in all patients. The chemokine receptor CXCR4 was significantly down‐ and IL‐4 upregulated in subjects with eosinophil increase. Conclusion: Our findings suggest that increased eosinophils in type 2 CRS are associated with a good clinical response to dupilumab. Patients with elevated IL‐4 at baseline developed dupilumab‐induced transient eosinophilia. We identified the downregulation of VCAM‐1 and surface markers CD49d and CXCR4 on eosinophils as possible explanations of dupilumab‐induced eosinophilia.
- Subjects
EOSINOPHILIA; SINUSITIS; CXCR4 receptors; DUPILUMAB; NASAL polyps; MONOCLONAL antibodies
- Publication
Allergy, 2023, Vol 78, Issue 10, p2712
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15844